Interestingly, Raina and his colleagues demonstrated that ARV‐771, a small molecule–based PROTAC using pan‐BET inhibitors suppressed both AR protein level and AR signalling, dramatically improved the efficacy in cellular models of castrate resistance prostate cancer (CRPC).68 The gene discussed is AR; the disease is Familial prostate cancer.